BASF plans to focus its pharmaceutical ingredients and services business within the Nutrition & Health division on its core expertise in pharmaceutical excipients, according to the company. BASF intends to divest its custom synthesis business and parts of its current active pharmaceutical ingredients (APIs) business to Siegfried Holding AG. APIs include ephedrine, pseudoephedrine and caffeine. BASF’s excipient portfolio and selected APIs, such as ibuprofen, omega-3 fatty acids and polyethylenglycol (PEG) will remain part of BASF’s portfolio.
The intended divestiture is subject to the successful completion of processes required by applicable law, including consultations with employee representations and the approval of the competent merger control authorities. The transaction comprises the divestment of BASF’s production sites in Minden, Germany; Evionnaz, Switzerland; and Saint-Vulbas, France. The enterprise value is approximately €270 million, according to the company. About 850 positions globally are affected by the transaction. BASF and Siegfried intend to transfer all affected employees to the acquiring company.
For more information, visit: www.basf.com